Probability of extraprostatic disease according to the percentage of positive biopsy cores in clinically localized prostate cancer

被引:6
作者
Valette, Thiago N. [1 ]
Antunes, Alberto A. [1 ]
Leite, Katia Moreira [1 ]
Srougi, Miguel [1 ]
机构
[1] Univ Sao Paulo, Sch Med, Div Urol, Sao Paulo, Brazil
来源
INTERNATIONAL BRAZ J UROL | 2015年 / 41卷 / 03期
关键词
Prostatic Neoplasms; Prostatectomy; RADICAL PROSTATECTOMY; ANTIGEN; RECURRENCE; PREDICTOR; BENEFIT; SEXTANT;
D O I
10.1590/S1677-5538.IBJU.2014.0223
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: Prediction of extraprostatic disease in clinically localized prostate cancer is relevant for treatment planning of the disease. The purpose of this study was to explore the usefulness of the percentage of positive biopsy cores to predict the chance of extraprostatic cancer. Materials and Methods: We evaluated 1787 patients with localized prostate cancer submitted to radical prostatectomy. The percentage of positive cores in prostate biopsy was correlated with the pathologic outcome of the surgical specimen. In the final analysis, a correlation was made between categorical ranges of positive cores (10% intervals) and the risk of extraprostatic extension and/or bladder neck invasion, seminal vesicles involvement or metastasis to iliac lymph nodes. Student's t test was used for statistical analysis. Results: For each 10% of positive cores we observed a progressive higher prevalence of extraprostatic disease. The risk of cancer beyond the prostate capsule for < 10% positive biopsy cores was 7.4% and it increased to 76.2% at the category 90-100% positive cores. In patients with Gleason grade 4 or 5, the risk of extraprostatic cancer prostate was higher than in those without any component 4 or 5. Conclusion: The percentage of positive cores in prostate biopsy can predict the risk of cancer outside the prostate. Our study shows that the percentage of positive prostate biopsy fragments helps predict the chance of extraprostatic cancer and may have a relevant role in the patient's management.
引用
收藏
页码:449 / 454
页数:6
相关论文
共 21 条
[1]   The percentage of positive biopsy cores as a predictor of disease recurrence in patients with prostate cancer treated with radical prostatectomy [J].
Antunes, AA ;
Srougi, M ;
Dall'oglio, MF ;
Crippa, A ;
Campagnari, JC ;
Leite, KRM .
BJU INTERNATIONAL, 2005, 96 (09) :1258-1263
[2]  
Antunes AA, 2007, INT BRAZ J UROL, V33, P484
[3]  
Antunes Alberto A., 2007, Int. braz j urol., V33, P477, DOI 10.1590/S1677-55382007000400004
[4]   A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy [J].
Babaian, RJ ;
Toi, A ;
Kamoi, K ;
Troncoso, P ;
Sweet, J ;
Evans, R ;
Johnston, D ;
Chen, M .
JOURNAL OF UROLOGY, 2000, 163 (01) :152-157
[5]   Radical prostatectomy versus watchful waiting in localized prostate cancer:: the Scandinavian Prostate Cancer Group-4 randomized trial [J].
Bill-Axelson, Anna ;
Holmberg, Lars ;
Filen, Frej ;
Ruutu, Mirja ;
Garmo, Hans ;
Busch, Christer ;
Nordling, Stig ;
Haggman, Michael ;
Andersson, Swen-Olof ;
Bratell, Stefan ;
Spangberg, Anders ;
Palmgren, Juni ;
Adami, Hans-Olov ;
Johansson, Jan-Erik .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (16) :1144-1154
[6]   Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Schultz, D ;
Fondurulia, J ;
Chen, MH ;
Tomaszewski, JE ;
Renshaw, AA ;
Wein, A ;
Richie, JP .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (06) :1164-1172
[7]   Survival Benefit of Radical Prostatectomy in Lymph Node-Positive Patients with Prostate Cancer [J].
Engel, Jutta ;
Bastian, Patrick J. ;
Baur, Helmut ;
Beer, Volker ;
Chaussy, Christian ;
Gschwend, Juergen E. ;
Oberneder, Ralph ;
Rothenberger, Karl H. ;
Stief, Christian G. ;
Hoelzel, Dieter .
EUROPEAN UROLOGY, 2010, 57 (05) :754-761
[8]   The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma [J].
Epstein, JI ;
Allsbrook, WC ;
Amin, MB ;
Egevad, LL ;
Bastacky, S ;
Beltrán, AL ;
Berner, A ;
Billis, A ;
Boccon-Gibod, L ;
Cheng, L ;
Civantos, F ;
Cohen, C ;
Cohen, MB ;
Datta, M ;
Davis, C ;
Delahunt, B ;
Delprado, W ;
Eble, JN ;
Foster, CS ;
Furusato, M ;
Gaudin, PB ;
Grignon, DJ ;
Humphrey, PA ;
Iczkowski, KA ;
Jones, EC ;
Lucia, S ;
McCue, PA ;
Nazeer, T ;
Oliva, E ;
Pan, CC ;
Pizov, G ;
Reuter, V ;
Samaratunga, H ;
Sebo, T ;
Sesterhenn, I ;
Shevchuk, M ;
Srigley, JR ;
Suzigan, S ;
Takahashi, H ;
Tamboli, P ;
Tan, PH ;
Têtu, B ;
Tickoo, S ;
Tomaszewski, JE ;
Troncoso, P ;
Tsuzuki, T ;
True, LD ;
van der Kwast, T ;
Wheeler, TM ;
Wojno, KJ .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (09) :1228-1242
[9]   Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate [J].
Eskew, LA ;
Bare, RL ;
McCullough, DL .
JOURNAL OF UROLOGY, 1997, 157 (01) :199-202
[10]   Percent of prostate needle biopsy cores with cancer is a significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: Results from the search database [J].
Freedland, SJ ;
Aronson, WJ ;
Terris, MK ;
Kane, CJ ;
Amling, CL ;
Dorey, F ;
Presti, JC .
JOURNAL OF UROLOGY, 2003, 169 (06) :2136-2141